ASH 2024 | An analysis of QoL outcomes for patients with early-stage CLL treated with ibrutinib in CLL12

So I will be presenting the quality of life abstract in the CLL12. So what we did there is look at the quality of life in the treatment-naïve asymptomatic CLL patients, which is one of the most interesting aspects of the study for us because the overall survival was not, there was no difference in the CLL12 study. So for us it was even more important to look at the quality of life of the patients. What we did see interestingly, so we checked regularly through the questionnaires, the validated questionnaires of the EORTC. The patients gave us about 90% of the patients sent a questionnaire back. And we did see that in terms of physical functioning and global health score, we did not see any differences in the baseline values. But interestingly, the patients that were treated with ibrutinib compared to the placebo patients, they did have a shorter time to improvement in the physical functioning as well as a shorter time to deterioration in the bruising, so like the ibrutinib-associated toxicity overall. So in conclusion we did not see major impacts of ibrutinib on the quality of life of the asymptomatic treatment-naive patients. But also we did not see a negative impact of ibrutinib which is very interesting except for the physical functioning which was better in ibrutinib and the shorter time to deterioration for bruising in ibrutinib.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.